Cargando…
Practical recommendations for timely, accurate diagnosis of symptomatic Alzheimer’s disease (MCI and dementia) in primary care: a review and synthesis
The critical role of primary care clinicians (PCCs) in Alzheimer’s disease (AD) prevention, diagnosis and management must evolve as new treatment paradigms and disease‐modifying therapies (DMTs) emerge. Our understanding of AD has grown substantially: no longer conceptualized as a late‐in‐life syndr...
Autores principales: | Liss, J. L., Seleri Assunção, S., Cummings, J., Atri, A., Geldmacher, D. S., Candela, S. F., Devanand, D. P., Fillit, H. M., Susman, J., Mintzer, J., Bittner, T., Brunton, S. A., Kerwin, D. R., Jackson, W. C., Small, G. W., Grossberg, G. T., Clevenger, C. K., Cotter, V., Stefanacci, R., Wise‐Brown, A., Sabbagh, M. N. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
John Wiley and Sons Inc.
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8359937/ https://www.ncbi.nlm.nih.gov/pubmed/33458891 http://dx.doi.org/10.1111/joim.13244 |
Ejemplares similares
-
Meaningful benefits: a framework to assess disease-modifying therapies in preclinical and early Alzheimer’s disease
por: Assunção, Sheila Seleri, et al.
Publicado: (2022) -
Neuropsychological comparison of incident MCI and prevalent MCI
por: Hansen, Allison, et al.
Publicado: (2018) -
Advancing Computerized Cognitive Training for MCI and Alzheimer's Disease in a Pandemic and Post-pandemic World
por: Bodner, Kaylee A., et al.
Publicado: (2020) -
Microcystin mcyA and mcyE Gene Abundances Are Not Appropriate Indicators of Microcystin Concentrations in Lakes
por: Beversdorf, Lucas J., et al.
Publicado: (2015) -
AGITATION IN ALZHEIMER'S DISEASE: A DECISION TREE FOR HEALTHCARE PROVIDERS
por: Grossberg, George, et al.
Publicado: (2022)